autologous cd34+ hematopoietic stem cells transduced ex-vivo with a gamma-globin lentiviral vector
Cell therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 30, 2010 (NCT01129544)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02186418 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2014 | Doris Duke Charitable Foundation, University of Cincinnati |
| NCT01410019 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2010 | Assistance Publique - Hôpitaux de Paris |
| NCT01129544 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2010 | Harvard University, University of California, Los Angeles, University of Cincinnati |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Cincinnati | Academic/Hospital | 2 | 1 | 1 | 2010 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Doris Duke Charitable Foundation | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2010 |
| University of California, Los Angeles | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1